Aimmune Therapeutics (AIMT) – Management Comments
-
Aimmune Therapeutics (AIMT) Confirms $2B Acquisition by Nestle at $34.50/Sh
-
Aimmune Therapeutics (AIMT) Reports New Data from Ph. 3 ARTEMIS Trial Showing Patients are Confident in Efficacy of Daily Treatment w/ PALFORZIA after 9-Mo
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to AIMT Stock Lookup